2021
-
Promising Results for Lurbinectedin in SCLC When Paired with Irinotecan
Combined treatment with lurbinectedin and irinotecan appears to pack quite a punch in patients with relapsed small cell lung cancer (SCLC) according to the results of a phase Ib/II trial […]
-
Deeper Understanding of EGFR Mutation Subgroups Will Further Personalize Treatment for NSCLC
New insights into the types of EGFR mutations that can arise in NSCLC may help guide decisions about the most appropriate targeted drugs for individual patients. A study by Jacqulyne […]
-
Trastuzumab Deruxtecan Potential New Treatment Options for HER2+ NSCLC
The novel antibody drug conjugate trastuzumab deruxtecan (T-DXd) demonstrated clinically meaningful and promising efficacy in patients with HER2-mutated NSCLC, according to interim results of the DESTINY-Lung01 trial, presented as part […]
-
New Nodal Descriptor Classification Potentially Better at Differentiating Patients
The IASLC’s proposed new classification of N descriptor is potentially better at differentiating patients with lung cancer into different stages, according to the results of a study presented during the […]
-
Targeting KRAS in Lung Cancer: The Past, Present, and Future
Although RAS mutations constitute some of the most common genetic alterations in patients with adenocarcinomas, efforts to target the RAS oncoprotein have not proven fruitful, not only in NSCLC but […]
-
Envisioning A Tobacco-Free Generation
Million-dollar ad campaign characters such as the Marlboro Man and Joe Camel lured many people to take up the tobacco habit through magazine ads and TV commercials. Gimmicks such as […]
-
Nivolumab Boosted Survival in Relapsed Mesothelioma
Nivolumab significantly improved investigator-reported progression-free survival and overall survival compared with placebo in patients with relapsed malignant mesothelioma, according to preliminary results of the CONFIRM phase III trial presented during […]
-
Sotorasib Shows Early Activity Against KRAS G12C Mutant NSCLC
The first-in-class KRAS G12C inhibitor sotorasib has demonstrated early, deep, and durable responses in the treatment of advanced NSCLC with KRAS G12C mutations, according to results from the registrational phase […]
-
KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC
Patients with metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 50% face greater toxicity without the benefit of enhanced efficacy when ipilimumab is combined with pembrolizumab in the […]
-
LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC
Primary results of the phase II Lung Cancer Mutation Consortium (LCMC) 3 clinical trial suggest that neoadjuvant atezolizumab may be a worthwhile treatment option for selected patients with resectable stage […]
View ILCN Archives
Provider Resources